EMA accepts GSK’s bepirovirsen filing in chronic hepatitis B

GSK has moved bepirovirsen one step closer to market in Europe, announcing that the European Medicines Agency accepted its marketing authorisation application for adults with chronic hepatitis B. The candidate, an antisense oligonucleotide designed to reduce viral proteins and support a functional cure approach, remains investigational, but the filing signals that regulators now consider the dossier complete enough for formal review. (investing.com)

The submission follows a pivotal readout in January 2026, when GSK reported that its phase 3 B-Well 1 and B-Well 2 trials met their primary endpoints. Across more than 1,800 participants in 29 countries, bepirovirsen plus standard of care produced statistically significant and clinically meaningful functional cure rates compared with standard care alone. In these studies, functional cure was defined as loss of hepatitis B surface antigen and undetectable HBV DNA for at least 24 weeks after a finite course of treatment. (gsk.com)

That matters because chronic hepatitis B remains difficult to clear with existing therapy. GSK says more than 250 million people worldwide live with the disease, and current nucleos(t)ide analogue treatment often requires lifelong use while delivering functional cure rates of only about 1%. The burden is also substantial in Europe, where reporting tied to the EMA filing cited an estimated 3.2 million people living with chronic hepatitis B. (gsk.com)

Bepirovirsen’s path here has been building for several years. In the phase 2b B-Clear trial, results published in the New England Journal of Medicine and presented at AASLD 2022 showed sustained clearance of HBsAg and HBV DNA in some patients, helping identify a subgroup with lower baseline HBsAg levels that appeared more likely to benefit. GSK later used that signal to shape phase 3 development, including stratification by HBsAg level in B-Well 2. (gsk.com)

GSK has also been positioning bepirovirsen as a potentially first-in-class product in a broader hepatitis B strategy. The company licensed the asset from Ionis Pharmaceuticals, and industry coverage has pointed to commercial interest in a finite-duration therapy that could shift treatment expectations beyond viral suppression alone. GSK has separately said it is studying sequential regimens that combine bepirovirsen with other modalities, including pegylated interferon and targeted immunotherapy, in an effort to raise cure rates further. (investing.com)

Expert commentary has been cautiously optimistic so far. In GSK’s earlier phase 2 announcement, principal investigator Professor Man-Fung Yuen said chronic hepatitis B is notoriously difficult to treat and highlighted the potential for functional cure, particularly in patients with low baseline HBsAg levels. That isn’t the same as independent reaction to the EMA filing itself, but it does reflect the clinical rationale that has carried the program into late-stage development and now into regulatory review. (gsk.com)

Why it matters: For veterinary professionals, this is mainly a cross-sector regulatory signal rather than a practice-changing development. It shows continued momentum behind antisense and finite-course antiviral strategies in chronic infectious disease, an area worth watching because platform advances in human medicine often influence translational research, regulatory thinking, and investment across animal health over time. More immediately, it’s another reminder that regulators are increasingly open to reviewing therapies built around functional cure endpoints, biomarker-guided patient selection, and combination or sequential treatment strategies rather than indefinite maintenance alone. That broader framework could have implications well beyond hepatitis B. (gsk.com)

What to watch: The biggest near-term questions are how quickly the EMA review moves, whether detailed phase 3 efficacy and safety data hold up in congress presentations and peer-reviewed publication later in 2026, and whether other regulators follow Europe and Japan in accepting or advancing filings. If those milestones land cleanly, bepirovirsen could emerge as one of the more closely watched liver disease launches on GSK’s late-stage pipeline. (investing.com)